Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From AkaRx Inc.
US FDA’s Record Year For Drug Approvals? Wall Street Is Unimpressed
Pace of new US drug approvals is unprecedented, but investors continue to shun biopharma industry. Uncertainty about pricing environment is clearly outweighing the favorable regulatory climate. Stocks in the sector closed the year down more than 15% are still trading well below 2015 levels.
Deal Watch: Opportunity Knocks For Partnerships In Asia
ApolloBio signs on to take Inovio's HPV immunotherapy into China and Senju and Fosun sign China partnerships – all part of a wave of Chinese companies looking to bring innovative new medicines to the Greater China markets. Meanwhile, GSK signs on with Indian CRO Syngene.
2016 Review: Refocus, Reduce, Reform The Watchwords In Japan
While reimbursement pricing issues and policies dominated the Japanese pharma market in 2016, there was also notable commercial activity during the year, although this was more about refocusing and reducing rather than major mergers and acquisitions.
2016 Review: Price Pressure Marks A Turbulent Year In Japan
If one theme dominated the Japanese pharma market in 2016 it was reimbursement pricing, with the regular price cuts in April being followed by political pressure over high-priced oncology drugs, and then major new reforms by the end of the year.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.